Fluticasone propionate
- Generic Name
- Fluticasone propionate
- Brand Names
- Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31F3O5S
- CAS Number
- 80474-14-2
- Unique Ingredient Identifier
- O2GMZ0LF5W
- Background
Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
- Associated Conditions
- Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
- Associated Therapies
- -
A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 82
- Registration Number
- NCT03443843
- Locations
- 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
- Conditions
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 260
- Registration Number
- NCT03317015
Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 158
- Registration Number
- NCT03273946
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT03240575
- Locations
- 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 165
- Registration Number
- NCT03207243
- Locations
- 🇺🇦
GSK Investigational Site, Kyiv, Ukraine
Efficacy of Intermittent Tiotropium in Early Childhood Wheezing
- Conditions
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03199976
- Locations
- 🇫🇮
Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland
Study of REGN3500 and Dupilumab in Patients With Asthma
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03112577
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
🇬🇧Celerion, Belfast, United Kingdom
🇬🇧Hammersmith Medicine Research, London, United Kingdom
Cardiovascular Function in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 76
- Registration Number
- NCT03055988
- Locations
- 🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany
🇩🇪Klinische Forschung Berlin GbR, Berlin, Germany
🇩🇪Praxis Dr. med. Claus Keller, Frankfurt, Germany
The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Joseph Dohar, MD
- Target Recruit Count
- 12
- Registration Number
- NCT03040596
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler
- Conditions
- Interventions
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 841
- Registration Number
- NCT02980133
- Locations
- 🇷🇺
Teva Investigational Site 50440, Tomsk, Russian Federation
🇬🇪Teva Investigational Site 81044, Tbilisi, Georgia
🇬🇪Teva Investigational Site 81040, Tbilisi, Georgia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.